Comparison of the Impact of High‐Dose DHA and EPA Supplementation on the Intravascular Kinetics of Very‐Low Density Lipoprotein Apolipoprotein C‐III
Abstract
Apolipoprotein C‐III (apoC‐III) is an emerging risk factor for cardiovascular disease (CVD) and its presence on very‐low density lipoproteins (VLDL) may enhance their atherogenicity, primarily by delaying their rate of catabolism. We have shown in a recent study that high‐dose supplementation with docosahexaenoic acid (DHA) led to more pronounced reductions in TG compared with eicosapentaenoic acid (EPA), but mechanisms remain unclear. The objective of this study was to compare the individual effect of EPA and DHA on VLDL‐apoC‐III metabolism in men and women at risk of CVD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2017
- Source ID
- 10.1096/fasebj.31.1_supplement.971.8
Entities
People
- André Tchernof
- Benoit Lamarche
- Cecile Vors
- Janie Allaire
- Marin Johanne
- Patrick Couture
Organizations
- Antarctic Sciences
- Defense Health Agency
- Laval University
- United States Department of Defense
- University Institute of Cardiology and Pulmonology